Skip to content
Mycamine(micafungin)
Mycamine (micafungin) is a small molecule pharmaceutical. Micafungin was first approved as Mycamine on 2005-03-16. It is used to treat candidemia and mycoses in the USA. It has been approved in Europe to treat candidiasis.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Mycamine (generic drugs available since 2019-05-17)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Micafungin sodium
Tradename
Company
Number
Date
Products
MYCAMINEAstellas PharmaN-021506 RX2005-03-16
2 products, RLD, RS
MICAFUNGINPar PharmaceuticalN-212156 RX2021-06-16
2 products, RLD, RS
MICAFUNGINTevaN-212125 PEND2021-07-30
2 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
micafunginANDA2023-06-15
mycamineNew Drug Application2022-07-14
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
candidemiaEFO_1001282D058387
mycosesD009181B35-B49
Agency Specific
FDA
EMA
Expiration
Code
MICAFUNGIN SODIUM, MYCAMINE, ASTELLAS
2023-06-20PED
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
J02: Antimycotics for systemic use
J02A: Antimycotics for systemic use
J02AX: Other antimycotics for systemic use in atc
J02AX05: Micafungin
HCPCS
Code
Description
J2248
Injection, micafungin sodium, 1 mg
Clinical
Clinical Trials
59 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CandidiasisD002177B3735310
Invasive candidiasisD058365EFO_1001283B3731239
CandidemiaD058387EFO_100128221227
AspergillosisD001228EFO_0007157B443115
NeutropeniaD009503D701113
Liver transplantationD016031EFO_0010682112
Myeloid leukemia acuteD015470C92.0112
Invasive pulmonary aspergillosisD055744B44.0112
Myelodysplastic syndromesD009190D4611
Morbid obesityD009767EFO_000107411
Show 6 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MycosesD009181B35-B4933410
Invasive fungal infectionsD0000727421135
Oral candidiasisD002180EFO_0007406B37.022
FungemiaD016469B4922
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hematologic diseasesD006402EFO_0005803D75.911
Febrile neutropeniaD06414711
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Graft vs host diseaseD006086D89.8111
Stem cell transplantationD03358111
Catheter-related infectionsD05549911
NeoplasmsD009369C8011
Bone marrow transplantationD01602611
CandidaD00217511
FeverD005334HP_0001945R50.911
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMICAFUNGIN
INNmicafungin
Description
Micafungin is a cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy. It has a role as an antiinfective agent. It is an echinocandin and an antibiotic antifungal drug.
Classification
Small molecule
Drug classantifungal antibiotics (undefined group)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCCOc1ccc(-c2cc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@H](O)CC(N)=O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)c(OS(=O)(=O)O)c5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)no2)cc1
Identifiers
PDB
CAS-ID235114-32-6
RxCUI325887
ChEMBL IDCHEMBL457547
ChEBI ID600520
PubChem CID477468
DrugBankDB01141
UNII IDR10H71BSWG (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,961 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
913 adverse events reported
View more details